Pacific Biosciences Of California (PACB) Capital Expenditures (QoQ) (2010 - 2026)
Pacific Biosciences Of California (PACB) Capital Expenditures (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn |
| 10 | Pacific Biosciences Of California | 381.79 Mn | 144.92 Mn | 12.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.90% |
| Mar 31, 2026 | 253.43% |
| Dec 31, 2025 | 1,101.16% |
| Sep 30, 2025 | -115.64% |
| Jun 30, 2025 | -60.40% |
| Mar 31, 2025 | -14.10% |
| Dec 31, 2024 | 305.46% |
| Sep 30, 2024 | -153.21% |
| Jun 30, 2024 | -61.87% |
| Mar 31, 2024 | 91.65% |
| Dec 31, 2023 | 143.86% |
| Sep 30, 2023 | -63.40% |
| Jun 30, 2023 | -39.05% |
| Mar 31, 2023 | -24.12% |
| Dec 31, 2022 | 17.07% |
| Sep 30, 2022 | 4.23% |
| Jun 30, 2022 | 10.47% |
| Mar 31, 2022 | 28.01% |
| Jun 30, 2021 | 291.27% |
| Mar 31, 2021 | 498.51% |